Barbara M. Bryant

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index5.7kcitations81works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(47), Multiple Myeloma Research and Treatments(39), Epigenetics and DNA Methylation(21), Cancer-related gene regulation(15), Histone Deacetylase Inhibitors Research(14)

Publications80 total

Cell line information from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Table S1 from Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes
2023Open Access
Supporting data Fig 4A from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supporting data Fig 3A, 3B, 4D, S6 from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary figure legends from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary tables from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Data from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary figures from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary figures from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary Materials and Methods from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Data from Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes
2023Open Access
Supporting data Fig 4A from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplemental Data from Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes
2023Open Access
Data from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Table S1 from Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes
2023Open Access
Supplementary Materials and Methods from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary tables from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Cell line information from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary figure legends from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplemental Data from Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Robert J. Sims(21), Jennifer A. Mertz(18), Andrew R. Conery(17), Charlie Hatton(15), Archana Bommi‐Reddy(11), Péter Sandy(9), George Mulligan(9), Patrick Trojer(9), Richard C. Centore(9), Kerry L. Spillane(8), Eneida Pardo(7), Florence Poy(7), Wee Joo Chng(6), James E. Audia(6), Jean-Christophe Harmange(6), Shivangi Joshi(6), Nicole E. Follmer(6), Patricia Greninger(6), Arnaud Amzallag(6), Cyril H. Benes(6)